ArticleRisk management and healthcare policy2025
Transforming Opioid Overdose Prevention in the United States: Leveraging FDA's Narcan Approval to Foster a Culture of Health.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The opioid crisis in the United States remains a major public health emergency, claiming over 100,000 lives annually, with potent synthetic opioids like fentanyl driving the surge in overdose deaths. In response, the US Food and Drug Administration's (FDA) approval of over-the-counter (OTC) Narcan represents a pivotal step toward expanding access to naloxone, a life-saving medication that reverses opioid overdoses. However, maximizing the public health impact of this measure requires more than increasing availability-it demands a comprehensive, systemic approach that fosters community engagement, advances harm reduction, and transforms healthcare delivery. This paper applies the Robert Wood Johnson Foundation's (RWJF) Culture of Health (COH) model to provide a structured framework for optimizing Narcan's impact. Through its four interconnected pillars, (1) making health a shared value, (2) fostering cross-sector collaboration, (3) ensuring equitable access, and (4) transforming healthcare systems, the COH model offers critical insights into building sustainable, community-wide overdose prevention strategies. Central to this effort is stigma reduction, as negative perceptions of opioid use disorder continue to undermine both public willingness to seek naloxone and healthcare providers' readiness to offer it. Within the COH framework, the paper examines evidence-based interventions that normalize naloxone use, innovative cross-sector partnerships that foster acceptance, and policy initiatives that expand access while addressing systemic inequities. By synthesizing real-world success stories, including community-based naloxone distribution programs, law enforcement-assisted interventions, and hospital-based harm reduction initiatives, this paper outlines a strategic blueprint for translating the FDA's Narcan ruling into lasting public health outcomes. It concludes with actionable recommendations for healthcare systems, policymakers, and public health agencies to institutionalize harm reduction practices and dismantle barriers to care. Only by embedding a Culture of Health into the fabric of healthcare, public health, and community systems can we achieve lasting progress against the opioid crisis and foster healthier, more equitable communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.